NCT04714177View on ClinicalTrials.gov

Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage

PHASE2UnknownINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

March 1, 2023

Study Completion Date

September 1, 2023

Conditions
Intracerebral Hemorrhage
Interventions
DRUG

Edaravone Dexborneol

Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage

DRUG

Placebo

Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage

Sponsors
All Listed Sponsors
collaborator

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY

lead

First Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT04714177 - Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage | Biotech Hunter | Biotech Hunter